E Lonn

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study
    Adefowope Odueyungbo
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON, Canada
    AIDS Res Ther 6:11. 2009
  2. ncbi Effect of long-term therapy with ramipril in high-risk women
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 40:693-702. 2002
  3. ncbi Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
    Eva Lonn
    Division of Cardiology and Population Health Institute, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    Curr Atheroscler Rep 4:363-72. 2002
  4. ncbi Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Hematol 14:481-7. 2007
  5. ncbi Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)
    Eva M Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 53:2028-35. 2009
  6. ncbi The clinical relevance of pharmacological blood pressure lowering mechanisms
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, Ontario
    Can J Cardiol 20:83B-88B. 2004
  7. ncbi Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions
    Eva Lonn
    Hamilton Health Sciences, General Site, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Curr Vasc Pharmacol 4:253-68. 2006
  8. ncbi Homocysteine lowering with folic acid and B vitamins in vascular disease
    Eva Lonn
    Population Health Research Institute, Hamilton General Hospital, McMaster University, and the Department of Medicine, Division of Cardiology, Hamilton Health Sciences, Hamilton, Ont
    N Engl J Med 354:1567-77. 2006
  9. ncbi Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Eur J Cardiovasc Prev Rehabil 10:420-8. 2003
  10. ncbi Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial
    E Lonn
    Hamilton Health Sciences Corporation, Hamilton, Ontario
    Can J Cardiol 22:47-53. 2006

Collaborators

Detail Information

Publications72

  1. ncbi Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study
    Adefowope Odueyungbo
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON, Canada
    AIDS Res Ther 6:11. 2009
    ..CONCLUSION: IMT correlates better than FMD with established cardiovascular risk factors in this cohort of HIV patients. Standardization of protocols for FMD and IMT will facilitate the comparison of results across studies...
  2. ncbi Effect of long-term therapy with ramipril in high-risk women
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 40:693-702. 2002
    ..We evaluated the effects of long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women...
  3. ncbi Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
    Eva Lonn
    Division of Cardiology and Population Health Institute, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    Curr Atheroscler Rep 4:363-72. 2002
    ..The use of combined ACE inhibitor plus ARB therapy offers theoretical advantages over the use of each of these agents alone and is also under investigation in large, randomized clinical trials...
  4. ncbi Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Hematol 14:481-7. 2007
    ....
  5. ncbi Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)
    Eva M Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 53:2028-35. 2009
    ....
  6. ncbi The clinical relevance of pharmacological blood pressure lowering mechanisms
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, Ontario
    Can J Cardiol 20:83B-88B. 2004
    ..Therefore, a uniform formula for the treatment of hypertension is not likely to achieve optimal results. Rather, treatment strategies based on careful, comprehensive and individualized patient assessments should be pursued...
  7. ncbi Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions
    Eva Lonn
    Hamilton Health Sciences, General Site, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Curr Vasc Pharmacol 4:253-68. 2006
    ..In addition systematic, sustainable and globally applicable approaches to the secondary prevention of cardiovascular diseases need to be developed to truly realize the vast potential benefits of existing therapies...
  8. ncbi Homocysteine lowering with folic acid and B vitamins in vascular disease
    Eva Lonn
    Population Health Research Institute, Hamilton General Hospital, McMaster University, and the Department of Medicine, Division of Cardiology, Hamilton Health Sciences, Hamilton, Ont
    N Engl J Med 354:1567-77. 2006
    ..Folic acid and vitamins B6 and B12 lower homocysteine levels. We assessed whether supplementation reduced the risk of major cardiovascular events in patients with vascular disease...
  9. ncbi Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Eur J Cardiovasc Prev Rehabil 10:420-8. 2003
    ..The prognostic significance of left ventricular hypertrophy (LVH) identified by simple electrocardiographic (ECG) criteria in high-risk patients with established cardiovascular (CV) diseases is not clearly understood...
  10. ncbi Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial
    E Lonn
    Hamilton Health Sciences Corporation, Hamilton, Ontario
    Can J Cardiol 22:47-53. 2006
    ..Therefore, a large, randomized clinical trial--the Heart Outcomes Prevention Evaluation (HOPE)-2 study--is being conducted to evaluate this therapy in patients at high risk for CV events...
  11. ncbi Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial
    Eva Lonn
    Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 43:2200-6. 2004
    ..The purpose of this study was to assess the effects of ramipril on left ventricular mass (LVM) and function in vascular disease patients with controlled blood pressure (BP) and with preserved left ventricular ejection fraction (LVEF)...
  12. ncbi Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy
    Eva Lonn
    Department of Medicine and Population Health Institute, McMaster University, Hamilton, Ontario, Canada
    Diabetes Care 25:1919-27. 2002
    ..However, data from randomized clinical trials are limited. Therefore, we evaluated the effects of vitamin E supplementation on major CV outcomes and on the development of nephropathy in people with diabetes...
  13. ncbi The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators
    S S Anand
    Preventive Cardiology and Therapeutics Research Program, Hamilton Civic Hospitals Research Centre, McMaster University, Ontario
    Can J Cardiol 14:1349-57. 1998
    ..The relationship between the conventional and emerging risk factors, and atherosclerosis, vascular disease and markers of end-organ damage will be evaluated between and within ethnic groups...
  14. ncbi Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)
    S S Anand
    Department of Medicine, McMaster University, Ontario, Canada
    Lancet 356:279-84. 2000
    ..To establish whether this variation can be explained by differences in disease risk factors and subclinical atherosclerosis, we undertook a population-based study of three ethnic groups in Canada: South Asians, Chinese, and Europeans...
  15. ncbi Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
    E Lonn
    Departments of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 103:919-25. 2001
    ....
  16. ncbi Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
    J Mathew
    Division of Cardiology, Department of Medicine, University of Iowa College of Medicine, Iowa City, and Galesburg Cottage Hospital, Galesburg, Illinois, USA
    Circulation 104:1615-21. 2001
    ..We determined whether the ACE inhibitor ramipril prevents the development and causes regression of ECG-LVH and whether these changes are associated with improved prognosis independent of blood pressure reduction...
  17. ncbi Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease
    Sonia S Anand
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 108:420-5. 2003
    ..Interventions to prevent atherosclerosis progression and improve fibrinolytic function require evaluation in this high-risk group...
  18. ncbi The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis
    H C Gerstein
    McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada
    Diabetologia 48:1749-55. 2005
    ....
  19. ncbi Myocardial infarction associated with recency of immigration to Ontario
    G Saposnik
    Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    QJM 103:253-8. 2010
    ..OBJECTIve: To determine the risk of AMI among new immigrants compared to long-term residents, and, among those who develop AMI, their short- and long-term mortality rate...
  20. ncbi The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences
    M J McQueen
    Hamilton Regional Laboratory Medicine Program, Department of Laboratory Medicine, St Joseph s Hospital, Hamilton, Ontario
    Scand J Clin Lab Invest Suppl 240:143-56. 2005
    ..Sub-studies completed and on-going into the predictive role of natriuretic peptides, infectious and inflammatory markers, provide insight into possible mechanisms of action of Ramipril...
  21. ncbi The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial
    Glen Sumner
    Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
    J Cardiovasc Electrophysiol 20:781-7. 2009
    ....
  22. ncbi Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population
    Jasmine Grewal
    The Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Atherosclerosis 197:435-42. 2008
    ..Subclinical atherosclerosis (SCA) as determined by carotid ultrasound is an independent predictor of myocardial infarction and stroke and can refine CV risk assessment...
  23. ncbi Venous thromboembolism in association with features of the metabolic syndrome
    J G Ray
    Department of Medicine, St Michael s Hospital, University of Toronto, Ontario M5B 1W8, Canada
    QJM 100:679-84. 2007
    ..However, whether each of these factors additively increases the risk of VTE is uncertain...
  24. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  25. ncbi Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP)
    S S Anand
    Preventive Cardiology and Therapeutics Research Program, Department of Medicine, McMaster University, Ontario, L8L 2X2, Hamilton, Canada
    Lancet 358:1147-53. 2001
    ..To establish the relative prevalence of risk factors, atherosclerosis, and CVD, we undertook a population-based study among people of Aboriginal and European ancestry in Canada...
  26. ncbi Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis
    Anwar T Merchant
    Population Health Research Institute, Hamilton, Ontario, Canada
    Am J Clin Nutr 87:168-74. 2008
    ..Intake of saturated fat, trans fat, and alcohol alter cardiovascular disease risk, but their effect on subclinical atherosclerosis remains understudied...
  27. ncbi Increased cardiovascular risk after pre-eclampsia in women with dysglycaemia
    S D McDonald
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada
    Diabet Med 30:e1-7. 2013
    ..Our objective was to determine if the high risk of cardiovascular disease in women with pre-eclampsia is accounted for by known cardiovascular risk factors including albuminuria...
  28. ncbi Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease
    Jean-Francois Dorval
    Division of Cardiology, McGill University Health Center, 687 Pine Avenue, Montreal, , Canada
    Am J Cardiol 95:249-53. 2005
    ....
  29. ncbi Cardiac function stratification based on echocardiographic or clinical markers of left ventricular filling pressures predicts death and hospitalization better than stratification by ventricular systolic function alone
    Kofo O Ogunyankin
    Queens University, Kingston General Hospital, Kingston, Ontario, Canada
    Echocardiography 25:169-81. 2008
    ..A normal left ventricular ejection fraction (LVEF) often underestimates the poor prognosis associated with diastolic dysfunction...
  30. ncbi Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial
    Gustavo Saposnik
    Department of Medicine, Division of Neurology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Stroke 40:1365-72. 2009
    ..Our aim was to determine whether vitamin therapy reduces the risk of ischemic and hemorrhagic stroke, as well as stroke-related disability...
  31. ncbi Use of carotid ultrasound to stratify risk
    E Lonn
    McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
    Can J Cardiol 17:22A-5A. 2001
    ..The validity and the usefulness of the technique - primarily as a research tool but also in the assessment of clinical cardiovascular risk - have been shown in a number of studies...
  32. ncbi Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth
    K M Morrison
    Mc Master University, HSC 3A59, 1200 Main Street W, Hamilton, ON, L8N 3Z5, Canada
    Atherosclerosis 208:501-5. 2010
    ..The age at which vascular changes can be reliably identified using IMT and the influence of CV risk factors beyond FH on IMT remains unclear...
  33. ncbi Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial
    Eva Lonn
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario
    JAMA 293:1338-47. 2005
    ..CONCLUSION: In patients with vascular disease or diabetes mellitus, long-term vitamin E supplementation does not prevent cancer or major cardiovascular events and may increase the risk for heart failure...
  34. ncbi Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial
    Joel G Ray
    Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Ann Intern Med 146:761-7. 2007
    ..Elevated total homocysteine levels are associated with a higher risk for venous thromboembolism. Whether decreasing homocysteine levels with vitamin therapy reduces the risk for venous thromboembolism is not known...
  35. ncbi Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension
    Jackie Bosch
    Division of Cardiology, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 112:1339-46. 2005
    ..6 years of follow-up and (2) observed in subgroups based on risk and ancillary treatments...
  36. ncbi Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction
    Jasmine Grewal
    Population Health Research Institute and McMaster University, Hamilton, Ontario
    Am J Cardiol 102:733-7. 2008
    ..6 to 24.8, p = 0.0003) as was BNP >100 pg/ml (hazard ratio 3.1, 95% CI 1.2 to 8.2, p = 0.02) in the BNP model. In conclusion, both elevated NT-proBNP and BNP are strong independent predictors of clinical events in patients with HF-PLVEF...
  37. ncbi C-reactive protein as a screening test for cardiovascular risk in a multiethnic population
    Sonia S Anand
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Arterioscler Thromb Vasc Biol 24:1509-15. 2004
    ..Small increases in the inflammatory marker C-reactive protein (CRP) are predictive of vascular events among asymptomatic individuals. There are few data supporting the use of CRP as a risk marker among nonwhite individuals...
  38. ncbi Use of ramipril in preventing stroke: double blind randomised trial
    Jackie Bosch
    Canadian Cardiovascular Collaboration, McMaster University, 237 Barton St E, Hamilton, ON, Canada L8L 2X2
    BMJ 324:699-702. 2002
    ..To determine the effect of the angiotensin converting enzyme inhibitor ramipril on the secondary prevention of stroke...
  39. ncbi Polypill: the evidence and the promise
    Eva Lonn
    Population Health Research Institute and Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Lipidol 20:453-9. 2009
    ....
  40. ncbi Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients
    Vineet Bhan
    Terrence Donnelly Heart Centre, St Michael s Hospital, University of Toronto, Ontario, Canada
    Am J Cardiol 106:1270-6. 2010
    ..Our findings underscore the opportunity to optimize the treatment of these high-risk patients...
  41. ncbi The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study
    Hertzel C Gerstein
    McMaster University and the Population Health Research Institute, Hamilton, Ontario, Canada
    Diabetes Care 26:144-9. 2003
    ..The relationship between dysglycemia and atherosclerosis (AS) in the general population and in different ethnic groups remains controversial...
  42. ncbi Risk of premature stroke in recent immigrants (PRESARIO): population-based matched cohort study
    G Saposnik
    Division of Neurology, Department of Medicine, St Michael s Hospital, University of Toronto, 55 Queen St E, Toronto, Ontario, M5C 1R6, Canada
    Neurology 74:451-7. 2010
    ..We determined the risk of acute stroke associated with recency of immigration...
  43. ncbi Antiatherosclerotic effects of ACE inhibitors: where are we now?
    E Lonn
    McMaster University, Hamilton, Ontario, Canada
    Am J Cardiovasc Drugs 1:315-20. 2001
    ....
  44. ncbi BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction
    Jasmine Grewal
    Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada
    Eur J Heart Fail 10:252-9. 2008
    ....
  45. ncbi Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study
    Marek Smieja
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 107:251-7. 2003
    ....
  46. ncbi Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample
    Matthew B Lanktree
    Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    J Lipid Res 50:1487-96. 2009
    ..The findings indicate the potential utility of the Illumina CVD beadchip, but they underscore the need to consider meta-analysis of results from commonly studied clinical or epidemiological samples...
  47. ncbi Prevalence of mitral valve prolapse in ethnic groups
    Michael Theal
    Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Canada
    Can J Cardiol 20:511-5. 2004
    ..From a population perspective, the prevalence of serious cardiovascular complications associated with MVP is low...
  48. ncbi Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention
    Eugene Crystal
    McMaster University, Hamilton, Ontario, Canada
    Am Heart J 145:174-8. 2003
    ..CONCLUSIONS: The clinical trial designed to evaluate LAA occlusion at the time of routine CABG surgery is currently in the pilot phase...
  49. ncbi Surrogates of surrogates: the story of hypertension and 24 h blood pressure monitoring
    Jasmine Grewal
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Can J Cardiol 21:639-42. 2005
    ..However, further evidence that the use of ABP monitoring can improve patients' clinical outcomes is needed and would make the use of this promising technique more compelling and more widely accepted...
  50. ncbi Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men
    Raymond T Yan
    Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario L8L 2X2, Canada
    J Am Coll Cardiol 45:1980-6. 2005
    ..Further studies are needed to define their role in clinical research and in cardiovascular risk assessment...
  51. ncbi The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases
    E Lonn
    HHSC, General Site, Barton Street East, Hamilton, ON, L8L2X2, Canada
    Pharmacoepidemiol Drug Saf 10:497-508. 2001
    ..A number of examples are also provided related to the use of surrogate endpoints in clinical trials with special emphasis on their use in cardiovascular medicine...
  52. ncbi Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study
    Omid Salehian
    Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am Heart J 154:448-53. 2007
    ..We evaluated the effect of angiotensin-converting enzyme (ACE) inhibitor ramipril on the incidence of atrial fibrillation (AF) in patients enrolled in the Heart Outcomes Prevention Evaluation trial...
  53. ncbi Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke
    Jeff S Healey
    McMaster University, Hamilton, Ontario, Canada
    Am Heart J 150:288-93. 2005
    ..This pilot study assessed the safety and efficacy of left atrial appendage (LAA) occlusion, performed at the time of coronary artery bypass grafting (CABG)...
  54. ncbi Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals
    Subodh Verma
    Division of Cardiac Surgery, Toronto General Hospital, Toronto, Canada
    Eur Heart J 25:1754-60. 2004
    ..These observations suggest that the predictive value of CRP may be largely independent of abnormalities in endothelial function. The additive prognostic value of endothelial vasodilator testing remains to be established...
  55. ncbi Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians
    Linda E Kelemen
    Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, USA
    Atherosclerosis 176:361-70. 2004
    ..Few studies have evaluated the associations of plasma homocysteine concentration, the methylenetetrahydrofolate reductase (MTHFR) C677T genotype and B vitamin concentration with intima media thickness (IMT) in multiethnic populations...
  56. ncbi The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes
    Andrew P Levy
    Diabetes Care 27:2767. 2004
  57. ncbi Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial
    Gilles R Dagenais
    Laval University Heart and Lung Institute, Ste Foy, Quebec G1V 4G5, Canada
    Eur J Cardiovasc Prev Rehabil 12:75-81. 2005
    ..In recent large cardiovascular trials done in stable patients, 14-31% of the participants were smokers; the consequences of smoking in these trials using medications known to reduce cardiovascular events, have not been assessed...
  58. ncbi Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study
    J Malcolm O Arnold
    London Health Sciences Centre, London, Canada
    Circulation 107:1284-90. 2003
    ..We assessed an angiotensin-converting enzyme (ACE) inhibitor, ramipril, to prevent the development of heart failure in high-risk patients without known low ejection fraction or heart failure...
  59. ncbi Homocysteine-lowering B vitamin therapy in cardiovascular prevention--wrong again?
    Eva Lonn
    JAMA 299:2086-7. 2008
  60. ncbi Randomized clinical trial of homocysteine level lowering therapy and fractures
    Anna M Sawka
    Toronto General Hospital, 200 Elizabeth St, 12-212 Eaton North, Toronto, Ontario M5G 2C4, Canada
    Arch Intern Med 167:2136-9. 2007
  61. ncbi Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review
    Monica Gianni
    Department of Clinical Medicine, University of Insubria, Varese, Italy
    Eur Heart J 27:1523-9. 2006
    ..CONCLUSION: Clinicians should consider this syndrome in the differential diagnosis of patients presenting with chest pain, especially in post-menopausal women with a recent history of emotional or physical stress...
  62. ncbi Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES
    Hans Persson
    Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital Department of Cardiology, Stockholm, Sweden
    J Am Coll Cardiol 49:687-94. 2007
    ..We tested the hypothesis that diastolic dysfunction (DD) was an important predictor of cardiovascular (CV) death or heart failure (HF) hospitalization in a subset of patients (ejection fraction [EF] >40%) in the CHARM-Preserved study...
  63. ncbi Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients
    Monica Gianni
    Department of Medicine, University of Insubria, Varese, Italy
    Eur Heart J 28:1382-8. 2007
    ..Cardiovascular (CV) disease is the leading cause of death in the elderly. The use of ACE-inhibitors in elderly patients with chronic stable vascular disease has not been previously reported...
  64. ncbi Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity
    Gilles R Dagenais
    Laval University Heart and Lung Institute, Ste Foy, Quebec, Canada
    Can J Cardiol 19:1387-91. 2003
    ..Such a relationship has not been assessed in patients with ICVD who may have a different occurrence due to their disease and medications...
  65. ncbi Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX)
    Francois Charbonneau
    Department of Cardiovascular Sciences and the Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada
    Atherosclerosis 197:420-7. 2008
    ..To evaluate the effect of the calcium channel blocker amlodipine on endothelial function in normotensive patients with coronary disease taking concomitant atorvastatin therapy...
  66. ncbi Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors
    Johannes F E Mann
    Department of Nephrology and Hypertension, Schwabing General Hospital, Ludwig Maximilians University, Munich, Germany
    Am J Cardiovasc Drugs 2:157-62. 2002
    ..In addition, there is evidence that ACE inhibitors improve renal outcomes in renal insufficiency. Prospective studies should test the predictive power of ERI for cardiovascular disease and therapeutic options...
  67. ncbi The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study
    Todd J Anderson
    Cardiovascular Division, Department of Medicine, University of Calgary, Alberta
    Can J Cardiol 19:61-6. 2003
    ..Quantitative B-mode ultrasound will be employed to assess endothelial function and subclinical atherosclerosis. This research is designed to redefine the approach to the primary prevention of atherosclerosis...
  68. ncbi Pathophysiologic and therapeutic importance of tissue ACE: a consensus report
    Victor J Dzau
    Department of Medicine, Brigham Women s Hospital, Boston, MA 02115, USA
    Cardiovasc Drugs Ther 16:149-60. 2002
    ..Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined...
  69. ncbi Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascula
    James H Stein
    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    J Am Soc Echocardiogr 21:93-111; quiz 189-90. 2008
  70. ncbi Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study
    Stefan Blankenberg
    Department of Medicine II, Johannes Gutenberg University Mainz, Mainz, Germany
    Circulation 114:201-8. 2006
    ....
  71. ncbi The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers
    Subodh Verma
    Division of Cardiac Surgery, Toronto General Hospital, 14 EN 215, 200 Elizabeth Street, Toronto, Ont, Canada M5G 2C4
    Atherosclerosis 182:361-5. 2005
    ..Long-term follow-up of the FATE study will shed light on whether the predictive value of sCD40L is independent of Framingham based global risk assessment...
  72. ncbi The T-786-->C mutation in endothelial nitric oxide synthase is associated with hypertension
    Matthew E Hyndman
    University of Calgary Department of Medicine, Calgary, Alberta, Canada
    Hypertension 39:919-22. 2002
    ..16(95% confidence interval, 1.3 to 3.7) more likely to be hypertensive. Therefore, the -786 C/C genotype in NO synthase is a significant contributing factor for increasing the risk of essential hypertension...